Please use this identifier to cite or link to this item:
|Title:||Rivaroxaban or Aspirin for extended treatment of venous thromboembolism|
|Author:||Weitz, Jeffrey I.|
Lensing, Anthonie W.A.
Prins, Martin H.
Brighton, Timothy A.
Cohen, Alexander T.
Davidson, Bruce L.
Freitas, Maria C.S.
Kakkar, Ajay K.
Van Bellen, Bonno
Pap, Akos F.
Berkowitz, Scott D.
Wells, Philip S.
Riera Mestre, Antoni
EINSTEIN CHOICE Investigators
|Publisher:||Massachusetts Medical Society|
|Abstract:||Background: although many patients with venous thromboembolism require extended treatment, it is uncertain whether it is better to use full- or lower-intensity anticoagulation therapy or aspirin. Methods: in this randomized, double-blind, phase 3 study, we assigned 3396 patients with venous thromboembolism to receive either once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin. All the study patients had completed 6 to 12 months of anticoagulation therapy and were in equipoise regarding the need for continued anticoagulation. Study drugs were administered for up to 12 months. The primary efficacy outcome was symptomatic recurrent fatal or nonfatal venous thromboembolism, and the principal safety outcome was major bleeding. Results: a total of 3365 patients were included in the intention-to-treat analyses (median treatment duration, 351 days). The primary efficacy outcome occurred in 17 of 1107 patients (1.5%) receiving 20 mg of rivaroxaban and in 13 of 1127 patients (1.2%) receiving 10 mg of rivaroxaban, as compared with 50 of 1131 patients (4.4%) receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. aspirin, 0.34; 95% confidence interval [CI], 0.20 to 0.59; hazard ratio for 10 mg of rivaroxaban vs. aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0.001 for both comparisons). Rates of major bleeding were 0.5% in the group receiving 20 mg of rivaroxaban, 0.4% in the group receiving 10 mg of rivaroxaban, and 0.3% in the aspirin group; the rates of clinically relevant nonmajor bleeding were 2.7%, 2.0%, and 1.8%, respectively. The incidence of adverse events was similar in all three groups. Conclusions: among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates. (Funded by Bayer Pharmaceuticals; EINSTEIN CHOICE ClinicalTrials.gov number, NCT02064439).|
|Note:||Reproducció del document publicat a: https://doi.org/10.1056/NEJMoa1700518|
|It is part of:||New England Journal of Medicine, 2017, vol. 376, num. 13, p. 1211-1222|
|Appears in Collections:||Articles publicats en revistes (Ciències Clíniques)|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.